BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, Weintraub D. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 2021;7:47. [PMID: 34210995 DOI: 10.1038/s41572-021-00280-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 51] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Gao F, Zhang H, Yang J, Cai M, Yang Q, Wang H, Xu Y, Chen H, Hu Y, He W, Zhang J. ATPase Thorase Deficiency Causes α-Synucleinopathy and Parkinson’s Disease-like Behavior. Cells 2022;11:2990. [DOI: 10.3390/cells11192990] [Reference Citation Analysis]
2 Chen F, Chen S, Si A, Luo Y, Hu W, Zhang Y, Ma J. The long-term trend of Parkinson’s disease incidence and mortality in China and a Bayesian projection from 2020 to 2030. Front Aging Neurosci 2022;14:973310. [DOI: 10.3389/fnagi.2022.973310] [Reference Citation Analysis]
3 Blasiak J, Sobczuk P, Pawlowska E, Kaarniranta K. Interplay between aging and other factors of the pathogenesis of age-related macular degeneration. Ageing Res Rev 2022;81:101735. [PMID: 36113764 DOI: 10.1016/j.arr.2022.101735] [Reference Citation Analysis]
4 Barbiero JK, Ramos DC, Boschen S, Bassani T, Da Cunha C, Vital MABF. Fenofibrate promotes neuroprotection in a model of rotenone-induced Parkinson's disease. Behav Pharmacol 2022. [PMID: 36094044 DOI: 10.1097/FBP.0000000000000699] [Reference Citation Analysis]
5 Luo J, Wu H, Li J, Xian W, Li W, Locascio JJ, Pei Z, Liu G. Joint Modeling Study Identifies Blood-Based Transcripts Link to Cognitive Decline in Parkinson's Disease. Mov Disord 2022. [PMID: 36087011 DOI: 10.1002/mds.29213] [Reference Citation Analysis]
6 Tong T, Duan W, Xu Y, Hong H, Xu J, Fu G, Wang X, Yang L, Deng P, Zhang J, He H, Mao G, Lu Y, Lin X, Yu Z, Pi H, Cheng Y, Xu S, Zhou Z. Paraquat exposure induces Parkinsonism by altering lipid profile and evoking neuroinflammation in the midbrain. Environ Int 2022;169:107512. [PMID: 36108500 DOI: 10.1016/j.envint.2022.107512] [Reference Citation Analysis]
7 Zhang T, Liu W, Gao S. Effects of mind-body exercises on cognitive impairment in people with Parkinson's disease: A mini-review. Front Neurol 2022;13:931460. [DOI: 10.3389/fneur.2022.931460] [Reference Citation Analysis]
8 Yu Y, Yan W, Xu X, Zhang K, Si L, Liu X, Wang J, Song J, Sun H, Li X. Response times for reflexive saccades correlate with cognition in parkinson's disease, not disease severity or duration. Front Neurol 2022;13:945201. [DOI: 10.3389/fneur.2022.945201] [Reference Citation Analysis]
9 Palmas MF, Etzi M, Pisanu A, Camoglio C, Sagheddu C, Santoni M, Manchinu MF, Pala M, Fusco G, De Simone A, Picci L, Mulas G, Spiga S, Scherma M, Fadda P, Pistis M, Simola N, Carboni E, Carta AR. The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate Cortex. Cells 2022;11:2628. [DOI: 10.3390/cells11172628] [Reference Citation Analysis]
10 Macaskill MR, Pitcher TL, Melzer TR, Myall DJ, Horne K, Shoorangiz R, Almuqbel MM, Livingston L, Grenfell S, Pascoe MJ, Marshall ET, Marsh S, Perry SE, Meissner WG, Theys C, Le Heron CJ, Keenan RJ, Dalrymple-alford JC, Anderson TJ. The New Zealand Parkinson’s progression programme. Journal of the Royal Society of New Zealand. [DOI: 10.1080/03036758.2022.2111448] [Reference Citation Analysis]
11 Sheng Y, Wang H, Chang X, Jin P, Lin S, Qian S, Xie J, Lu W, Yu X. Effect of Scalp Nerve Block Combined with Intercostal Nerve Block on the Quality of Recovery in Patients with Parkinson’s Disease after Deep Brain Stimulation: Protocol for a Randomized Controlled Trial. Brain Sciences 2022;12:1007. [DOI: 10.3390/brainsci12081007] [Reference Citation Analysis]
12 Li X, Chen Z, Yue Y, Zhou X, Gu S, Tao J, Guo H, Zhu M, Du Q. Effect of Wearable Sensor-Based Exercise on Musculoskeletal Disorders in Individuals With Neurodegenerative Diseases: A Systematic Review and Meta-Analysis. Front Aging Neurosci 2022;14:934844. [DOI: 10.3389/fnagi.2022.934844] [Reference Citation Analysis]
13 Guo M, Ji X, Liu J. Hypoxia and Alpha-Synuclein: Inextricable Link Underlying the Pathologic Progression of Parkinson's Disease. Front Aging Neurosci 2022;14:919343. [DOI: 10.3389/fnagi.2022.919343] [Reference Citation Analysis]
14 Wang J, Zhang W, Zhou Y, Jia J, Li Y, Liu K, Ye Z, Jin L. Altered Prefrontal Blood Flow Related With Mild Cognitive Impairment in Parkinson's Disease: A Longitudinal Study. Front Aging Neurosci 2022;14:896191. [DOI: 10.3389/fnagi.2022.896191] [Reference Citation Analysis]
15 Bourdès V, Dogterom P, Aleman A, Parmantier P, Colas D, Lemarchant S, Marie S, Chou T, Abd-Elaziz K, Godfrin Y. Safety, Tolerability, Pharmacokinetics and Initial Pharmacodynamics of a Subcommissural Organ-Spondin-Derived Peptide: A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose First-in-Human Study. Neurol Ther 2022. [PMID: 35779189 DOI: 10.1007/s40120-022-00380-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Wang L, Zhang W, Liu F, Mao C, Liu CF, Cheng W, Feng J. Association of Cerebrospinal Fluid Neurofilament Heavy Protein Levels With Clinical Progression in Patients With Parkinson Disease. JAMA Netw Open 2022;5:e2223821. [PMID: 35881392 DOI: 10.1001/jamanetworkopen.2022.23821] [Reference Citation Analysis]
17 Bringas Vega ML, Pedroso Ibáñez I, Razzaq FA, Zhang M, Morales Chacón L, Ren P, Galan Garcia L, Gan P, Virues Alba T, Lopez Naranjo C, Jahanshahi M, Bosch-bayard J, Valdes-sosa PA. The Effect of Neuroepo on Cognition in Parkinson’s Disease Patients Is Mediated by Electroencephalogram Source Activity. Front Neurosci 2022;16:841428. [DOI: 10.3389/fnins.2022.841428] [Reference Citation Analysis]
18 Zhuang J, Jia J. Effects of Respiratory Muscle Strength Training on Respiratory-Related Impairments of Parkinson's Disease. Front Aging Neurosci 2022;14:929923. [DOI: 10.3389/fnagi.2022.929923] [Reference Citation Analysis]
19 Zhou Y, Zhen Y, Wang G, Liu B. Deconvoluting the Complexity of Reactive Oxygen Species (ROS) in Neurodegenerative Diseases. Front Neuroanat 2022;16:910427. [PMID: 35756499 DOI: 10.3389/fnana.2022.910427] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Yang N, Ju Y, Ren J, Wang H, Li P, Ning H, Tao J, Liu W. Prevalence and affective correlates of subjective cognitive decline in patients with de novo Parkinson's disease. Acta Neurol Scand 2022. [PMID: 35722712 DOI: 10.1111/ane.13662] [Reference Citation Analysis]
21 Jellinger KA. Morphological basis of Parkinson disease-associated cognitive impairment: an update. J Neural Transm (Vienna) 2022. [PMID: 35726096 DOI: 10.1007/s00702-022-02522-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 de Paula JJ, Paiva RERP, Souza-Silva NG, Rosa DV, Duran FLS, Coimbra RS, Costa DS, Dutenhefner PR, Oliveira HSD, Camargos ST, Vasconcelos HMM, de Oliveira Carvalho N, da Silva JB, Silveira MB, Malamut C, Oliveira DM, Molinari LC, de Oliveira DB, Januário JN, Silva LC, De Marco LA, Queiroz DMM, Meira W, Busatto G, Miranda DM, Romano-Silva MA. Selective visuoconstructional impairment following mild COVID-19 with inflammatory and neuroimaging correlation findings. Mol Psychiatry 2022. [PMID: 35701598 DOI: 10.1038/s41380-022-01632-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Pagonabarraga J, Pérez-González R, Bejr-Kasem H, Marín-Lahoz J, Horta-Barba A, Martinez-Horta S, Aracil-Bolaños I, Sampedro F, Campolongo A, Rivas E, Puig-Davi A, Ruiz-Barrios I, Pérez-Pérez J, Pascual-Sedano B, Kulisevsky J. Dissociable contribution of plasma NfL and p-tau181 to cognitive impairment in Parkinson's disease. Parkinsonism Relat Disord 2022:S1353-8020(22)00151-1. [PMID: 35752549 DOI: 10.1016/j.parkreldis.2022.05.020] [Reference Citation Analysis]
24 Weinshel S, Irwin DJ, Zhang P, Weintraub D, Shaw LM, Siderowf A, Xie SX. Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer's Disease to Parkinson's Disease. J Parkinsons Dis 2022;12:1155-67. [PMID: 35431261 DOI: 10.3233/JPD-212989] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Borda MG, Pérez-Zepeda MU, Jaramillo-Jimenez A, Chaudhuri KR, Tovar-Rios DA, Wallace L, Batzu L, Rockwood K, Tysnes OB, Aarsland D, Alves G. Frailty in Parkinson's disease and its association with early dementia: A longitudinal study. Parkinsonism Relat Disord 2022;99:51-7. [PMID: 35598420 DOI: 10.1016/j.parkreldis.2022.05.004] [Reference Citation Analysis]
26 Tsanov M. Basal Forebrain Impairment: Understanding the Mnemonic Function of the Septal Region Translates in Therapeutic Advances. Front Neural Circuits 2022;16:916499. [DOI: 10.3389/fncir.2022.916499] [Reference Citation Analysis]
27 Arioli M, Cattaneo Z, Rusconi ML, Blandini F, Tettamanti M. Action and emotion perception in Parkinson's disease: A neuroimaging meta-analysis. Neuroimage Clin 2022;35:103031. [PMID: 35569229 DOI: 10.1016/j.nicl.2022.103031] [Reference Citation Analysis]
28 Shkodina AD, Tarianyk KA, Boiko DI, Zehravi M, Akter S, Md Ashraf G, Rahman H. Cognitive and affective disturbances in patients with Parkinson's disease: perspectives for classifying of motor/neuropsychiatric subtypes. Neuroscience Letters 2022. [DOI: 10.1016/j.neulet.2022.136675] [Reference Citation Analysis]
29 Nabizadeh F, Pirahesh K, Valizadeh P. REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson’s disease: a cross-sectional and longitudinal study. J Neurol. [DOI: 10.1007/s00415-022-11120-z] [Reference Citation Analysis]
30 Uyar M, Lezius S, Buhmann C, Pötter-Nerger M, Schulz R, Meier S, Gerloff C, Kuhle J, Choe CU. Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson's Disease (MARK-PD Study). Mov Disord 2022. [PMID: 35384057 DOI: 10.1002/mds.29009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
31 Wianny F, Dzahini K, Fifel K, Wilson CRE, Bernat A, Dolmazon V, Misery P, Lamy C, Giroud P, Cooper HM, Knoblauch K, Procyk E, Kennedy H, Savatier P, Dehay C, Vezoli J. Induced Cognitive Impairments Reversed by Grafts of Neural Precursors: A Longitudinal Study in a Macaque Model of Parkinson's Disease. Adv Sci (Weinh) 2022;9:e2103827. [PMID: 35137562 DOI: 10.1002/advs.202103827] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Ceballos-Baumann A. [Parkinson's Disease - What is New?]. Dtsch Med Wochenschr 2022;147:337-43. [PMID: 35291040 DOI: 10.1055/a-1646-6321] [Reference Citation Analysis]
33 Chintalapudi N, Battineni G, Hossain MA, Amenta F. Cascaded Deep Learning Frameworks in Contribution to the Detection of Parkinson’s Disease. Bioengineering 2022;9:116. [DOI: 10.3390/bioengineering9030116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Huang R, Gao Y, Chen J, Duan Q, He P, Zhang J, Huang H, Zhang Q, Ma G, Zhang Y, Nie K, Wang L. TGR5 agonist INT-777 alleviates inflammatory neurodegeneration in parkinson’s disease mouse model by modulating mitochondrial dynamics in microglia. Neuroscience 2022. [DOI: 10.1016/j.neuroscience.2022.02.028] [Reference Citation Analysis]
35 He L, Wang J, Yang Y, Li J, Tu H. Mitochondrial Sirtuins in Parkinson’s Disease. Neurochem Res. [DOI: 10.1007/s11064-022-03560-w] [Reference Citation Analysis]
36 Říha P, Brabenec L, Mareček R, Rektor I, Rektorová I. The reduction of hippocampal volume in Parkinson's disease. J Neural Transm (Vienna) 2022. [PMID: 35122140 DOI: 10.1007/s00702-021-02451-8] [Reference Citation Analysis]
37 Ben Hassen C, Fayosse A, Landré B, Raggi M, Bloomberg M, Sabia S, Singh-Manoux A. Association between age at onset of multimorbidity and incidence of dementia: 30 year follow-up in Whitehall II prospective cohort study. BMJ 2022;376:e068005. [PMID: 35110302 DOI: 10.1136/bmj-2021-068005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
38 Szwedo AA, Dalen I, Pedersen KF, Camacho M, Bäckström D, Forsgren L, Tzoulis C, Winder-Rhodes S, Hudson G, Liu G, Scherzer CR, Lawson RA, Yarnall AJ, Williams-Gray CH, Macleod AD, Counsell CE, Tysnes OB, Alves G, Maple-Grødem J; Parkinson's Incidence Cohorts Collaboration. GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study. Mov Disord 2022. [PMID: 35106798 DOI: 10.1002/mds.28932] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
39 Banerjee R, Rai A, Iyer SM, Narwal S, Tare M. Animal models in the study of Alzheimer's disease and Parkinson's disease: A historical perspective. Anim Models and Exp Med. [DOI: 10.1002/ame2.12209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Liu J, Zhang Y, Ye T, Yu Q, Yu J, Yuan S, Gao X, Wan X, Zhang R, Han W, Zhang Y. Effect of Coffee against MPTP-Induced Motor Deficits and Neurodegeneration in Mice Via Regulating Gut Microbiota. J Agric Food Chem 2022;70:184-95. [PMID: 35016506 DOI: 10.1021/acs.jafc.1c06998] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
41 Horsager J, Knudsen K, Sommerauer M. Clinical and imaging evidence of brain-first and body-first Parkinson's disease. Neurobiol Dis 2022;:105626. [PMID: 35031485 DOI: 10.1016/j.nbd.2022.105626] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
42 Nadeem MS, Kazmi I, Ullah I, Muhammad K, Anwar F. Allicin, an Antioxidant and Neuroprotective Agent, Ameliorates Cognitive Impairment. Antioxidants 2022;11:87. [DOI: 10.3390/antiox11010087] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
43 Ravichandran KA, Heneka MT. Inflammasome activation in neurodegenerative diseases. Essays Biochem 2021;65:885-904. [PMID: 34846519 DOI: 10.1042/EBC20210021] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
44 Zhang L, Dai L, Li D. Mitophagy in neurological disorders. J Neuroinflammation 2021;18:297. [PMID: 34937577 DOI: 10.1186/s12974-021-02334-5] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
45 Pan C, Ren J, Hua P, Yan L, Yu M, Wang Y, Zhou G, Zhang R, Chen J, Liu W. Subjective Cognitive Complaints in Newly-Diagnosed Parkinson's Disease With and Without Mild Cognitive Impairment. Front Neurosci 2021;15:761817. [PMID: 34899165 DOI: 10.3389/fnins.2021.761817] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Jo S, Park KW, Hwang YS, Lee SH, Ryu HS, Chung SJ. Microarray Genotyping Identifies New Loci Associated with Dementia in Parkinson's Disease. Genes (Basel) 2021;12:1975. [PMID: 34946922 DOI: 10.3390/genes12121975] [Reference Citation Analysis]
47 Liu Y, Jiang H, Qin X, Tian M, Zhang H. PET imaging of reactive astrocytes in neurological disorders. Eur J Nucl Med Mol Imaging 2021. [PMID: 34873637 DOI: 10.1007/s00259-021-05640-5] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
48 Xu Q, Zhou M, Jiang C, Wu L, He Q, Zhao L, Dong Y, Liu J, Chen W. Application of the Chinese Version of the Montreal Cognitive Assessment-Basic for Assessing Mild Cognitive Impairment in Parkinson's Disease. Brain Sci 2021;11:1575. [PMID: 34942877 DOI: 10.3390/brainsci11121575] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Memou A, Dimitrakopoulos L, Kedariti M, Kentros M, Lamprou A, Petropoulou-Vathi L, Valkimadi PE, Rideout HJ. Defining (and blocking) neuronal death in Parkinson's disease: Does it matter what we call it? Brain Res 2021;1771:147639. [PMID: 34492263 DOI: 10.1016/j.brainres.2021.147639] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Barrett MJ, Sargent L, Nawaz H, Weintraub D, Price ET, Willis AW. Antimuscarinic Anticholinergic Medications in Parkinson Disease: To Prescribe or Deprescribe? Mov Disord Clin Pract 2021;8:1181-8. [PMID: 34765683 DOI: 10.1002/mdc3.13347] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Di Stefano A, Marinelli L. Advances in Parkinson's Disease Drugs. Biomolecules 2021;11:1640. [PMID: 34827638 DOI: 10.3390/biom11111640] [Reference Citation Analysis]
52 Bai S, Liu W, Guan Y. The Visuospatial and Sensorimotor Functions of Posterior Parietal Cortex in Drawing Tasks: A Review. Front Aging Neurosci 2021;13:717002. [PMID: 34720989 DOI: 10.3389/fnagi.2021.717002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 De Miranda BR, Goldman SM, Miller GW, Greenamyre JT, Dorsey ER. Preventing Parkinson's Disease: An Environmental Agenda. J Parkinsons Dis 2021. [PMID: 34719434 DOI: 10.3233/JPD-212922] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
54 Trompeta C, Fernández Rodríguez B, Gasca-Salas C. What Do We Know about Theory of Mind Impairment in Parkinson's Disease? Behav Sci (Basel) 2021;11:130. [PMID: 34677223 DOI: 10.3390/bs11100130] [Reference Citation Analysis]